company background image
1530 logo

3SBio SZSC:1530 Stock Report

Last Price

HK$7.39

Market Cap

HK$17.4b

7D

15.3%

1Y

12.8%

Updated

06 Oct, 2024

Data

Company Financials +

1530 Stock Overview

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends3/6

3SBio Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for 3SBio
Historical stock prices
Current Share PriceHK$7.39
52 Week HighHK$7.69
52 Week LowHK$4.91
Beta0.68
11 Month Change26.54%
3 Month Change17.30%
1 Year Change12.82%
33 Year Change0.54%
5 Year Change-45.10%
Change since IPO-5.86%

Recent News & Updates

Recent updates

Shareholder Returns

1530HK BiotechsHK Market
7D15.3%15.8%9.6%
1Y12.8%12.4%27.2%

Return vs Industry: 1530 matched the Hong Kong Biotechs industry which returned 12.4% over the past year.

Return vs Market: 1530 underperformed the Hong Kong Market which returned 27.2% over the past year.

Price Volatility

Is 1530's price volatile compared to industry and market?
1530 volatility
1530 Average Weekly Movement5.5%
Biotechs Industry Average Movement9.3%
Market Average Movement7.9%
10% most volatile stocks in HK Market17.4%
10% least volatile stocks in HK Market3.8%

Stable Share Price: 1530 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1530's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19935,607Jing Louwww.3sbio.com

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium.

3SBio Inc. Fundamentals Summary

How do 3SBio's earnings and revenue compare to its market cap?
1530 fundamental statistics
Market capHK$17.41b
Earnings (TTM)HK$1.83b
Revenue (TTM)HK$9.27b

9.5x

P/E Ratio

1.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1530 income statement (TTM)
RevenueCN¥8.42b
Cost of RevenueCN¥1.18b
Gross ProfitCN¥7.24b
Other ExpensesCN¥5.58b
EarningsCN¥1.66b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.70
Gross Margin85.94%
Net Profit Margin19.69%
Debt/Equity Ratio24.7%

How did 1530 perform over the long term?

See historical performance and comparison

Dividends

3.4%

Current Dividend Yield

33%

Payout Ratio